Allogene Therapeutics, Inc. Common Stock
Here’s whether Allogene Therapeutics, Inc. Common Stock (ALLO) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bullish.
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+8.45% over 10 days); RSI 53 — healthy momentum range; strong 1-year return of +70.7%; 3-month momentum positive (+46.6%); rising volume confirms the move (2.10x 30d avg). Currently 46.4% off its 52-week high. Score: +8/7.
ALLO is in a confirmed uptrend, trading above both its 50-day ($2.32) and 200-day ($1.56) moving averages. An RSI of 52.6 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +70.7% compares to +35.1% for SPY (beat the market by 35.6%). The current 46.4% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.